A review of Australian Medical Benefits Schedule (AMBS) data from 2005 to 2011 demonstrates a dramatic rise in intravitreal injections from 6,867 procedures in 2005 to 189,759 in 2011 (Fig. 1A).16 Using a prevalence of 3.5% to 11.6% based on retrospective data,9-12 one would predict a large volume of glaucoma work generated by anti-VEGF injections. This evidence concerns the gene VEGFA and glaucoma.